AZTA vs JNJ: fair value comparison
Azenta, Inc. and Johnson & Johnson · Updated 2026-10-19
Both currently screen as overvalued on TickrTrends' Forward Fair Value model. Within Healthcare, JNJ currently sits closer to the top of our ranking by discount to fair value.
| AZTA | JNJ | |
|---|---|---|
| Verdict | Overvalued | Overvalued |
| Last price | $34.09 | $261.44 |
| 12-month range | $16.02–$42.73 | $186.00–$278.43 |
| Rank by discount to fair value | #107 of 108 Healthcare | #87 of 108 Healthcare |
| Quality grade | D | D |
| Leverage | Low | Low |
| Margin trend | Contracting | Stable |
| Revenue growth | Declining | Modest |
| RSI zone | Neutral | Neutral |
| 50/200-day trend | Mixed | — |
| 52-week position | The upper-middle quarter | The top quarter |
Full single-stock breakdowns: AZTA fair value analysis · JNJ fair value analysis